GoAI
Get started
Viridian Therapeutics, Inc. logo

Viridian Therapeutics, Inc.

VRDN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$24.29

−$0.21 · -0.86%

Aug 21, 4:00 PM ET

Pre-market

$24.25

−$0.04 · -0.16%

Aug 24, 7:38 AM ET

VRDN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

64

Undervalued

Momentum

42

Neutral

Sentiment

76

Bullish

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Stephen F. Mahoney
Listed since
Jun 18, 2014
Employees
252

Market position

Day range

Current $24.29

52-week range

Current $24.29

Open
$24.65
Previous close
$24.50
Volume
906.3K
0.39× average
Average volume
2.31M
Average daily volume
Market cap
2.75B USD
Beta
0.94
Market reference 1
50-day average
$19.7476
+23.00% above average
200-day average
$23.9769
+1.31% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.48B USD
P/E (TTM)
-6.88×
P/B (TTM)
3.96×
P/S (TTM)
38.69×
EV / EBITDA
-7.35×
Earnings yield
-12.98%
Free cash flow yield
-10.49%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
99.38%
Operating margin
-569.68%
Net margin
-544.06%
Return on equity
-47.44%
Return on assets
-38.09%
Return on invested capital
-43.81%

Financial health

Debt / equity
0.37×
Current ratio
12.65×
Altman Z-score
1.84
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends10012%-29635%-69283%-108930%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -2690.79%Operating margin, FY2022: -7579.23%Operating margin, FY2023: -81035.03%Operating margin, FY2024: -99018.21%Operating margin, FY2025: -512.91%Net margin, FY2021: -2680.16%Net margin, FY2022: -7329.23%Net margin, FY2023: -75711.46%Net margin, FY2024: -89387.09%Net margin, FY2025: -483.57%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -2690.79%. Operating margin FY2022 -7579.23%. Operating margin FY2023 -81035.03%. Operating margin FY2024 -99018.21%. Operating margin FY2025 -512.91%. Net margin FY2021 -2680.16%. Net margin FY2022 -7329.23%. Net margin FY2023 -75711.46%. Net margin FY2024 -89387.09%. Net margin FY2025 -483.57%.

Income trends

Revenue

70.85M USD+23359.93%

Operating income

−363.4M USD-21.52%

Net income

−342.6M USD-26.91%
Income trends across reported periods114.27M USD−59.42M USD−233.12M USD−406.82M USDRevenue, FY2021: 2.96M USDRevenue, FY2022: 1.77M USDRevenue, FY2023: 314K USDRevenue, FY2024: 302K USDRevenue, FY2025: 70.85M USDOperating income, FY2021: −79.73M USDOperating income, FY2022: −134.3M USDOperating income, FY2023: −254.45M USDOperating income, FY2024: −299.04M USDOperating income, FY2025: −363.4M USDNet income, FY2021: −79.41M USDNet income, FY2022: −129.87M USDNet income, FY2023: −237.73M USDNet income, FY2024: −269.95M USDNet income, FY2025: −342.6M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.96M USD. Revenue FY2022 1.77M USD. Revenue FY2023 314K USD. Revenue FY2024 302K USD. Revenue FY2025 70.85M USD. Operating income FY2021 −79.73M USD. Operating income FY2022 −134.3M USD. Operating income FY2023 −254.45M USD. Operating income FY2024 −299.04M USD. Operating income FY2025 −363.4M USD. Net income FY2021 −79.41M USD. Net income FY2022 −129.87M USD. Net income FY2023 −237.73M USD. Net income FY2024 −269.95M USD. Net income FY2025 −342.6M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue70.85M USD302K USD314K USD1.77M USD2.96M USD
Gross profit70.85M USD302K USD314K USD1.77M USD2.96M USD
Research and development338.93M USD238.25M USD159.77M USD100.89M USD56.89M USD
Selling, general, and administrative95.32M USD61.08M USD95M USD35.18M USD25.81M USD
Operating expenses434.24M USD299.34M USD254.76M USD136.08M USD82.69M USD
Interest income27.4M USD32.13M USD18.56M USD4.92M USD318K USD
Interest expense4.95M USD3.05M USD1.85M USD486K USD3K USD
Depreciation and amortization460K USD1.24M USD522K USD255K USD120K USD
Operating income−363.4M USD−299.04M USD−254.45M USD−134.3M USD−79.73M USD
Net income−342.6M USD−269.95M USD−237.73M USD−129.87M USD−79.41M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 5 misses, 1 met estimate
Average EPS surprise
+4.82%
11 comparable reports
Latest EPS result
-1.05
Estimate -1.03 · Miss by 1.94%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.29-0.57-0.86-1.14Q1 '25BeatQ2 '25BeatQ3 '25MetQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.81, estimate -1.05, surprise +22.86%, Beat. Q2 2025, reported May 6, 2025: actual -0.87, estimate -0.95, surprise +8.42%, Beat. Q3 2025, reported Aug 6, 2025: actual -1, estimate -1, surprise 0.00%, Met estimate. Q4 2025, reported Nov 5, 2025: actual -0.34, estimate -0.82, surprise +58.54%, Beat. Q1 2026, reported Feb 26, 2026: actual -1.08, estimate -0.9, surprise -20.00%, Miss. Q2 2026, reported May 5, 2026: actual -0.9, estimate -1.06, surprise +15.09%, Beat. Q3 2026, reported Aug 6, 2026: actual -1.05, estimate -1.03, surprise -1.94%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.989, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates76.21M50.82M25.42M30.67KQ1 '25BeatQ2 '25BeatQ3 '25No estimateQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 72K USD, estimate 50K USD, surprise +44.00%, Beat. Q2 2025, reported May 6, 2025: actual 72K USD, estimate 44.08K USD, surprise +63.34%, Beat. Q3 2025, reported Aug 6, 2025: actual 75K USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 5, 2025: actual 70.57M USD, estimate 15.75M USD, surprise +348.06%, Beat. Q1 2026, reported Feb 26, 2026: actual 132K USD, estimate 18.38M USD, surprise -99.28%, Miss. Q2 2026, reported May 5, 2026: actual 141K USD, estimate 36.08K USD, surprise +290.77%, Beat. Q3 2026, reported Aug 6, 2026: actual 284K USD, estimate 56.36K USD, surprise +403.87%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 4.03M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$37.25

53.36% upside
Past 12 months12-month forecastHigh $45.00Average $37.25Low $26.00

Rating distribution

16 ratings
Strong buy00%
Buy1488%
Hold213%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions

VRDN news

defenseworld.net

Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN

Deutsche Bank AG bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 482,875 shares of the…

Read source
globenewswire.com

Viridian Reports Continuation of Massive Sulphides at Kraken Main; First Assays Pending

OTTAWA, Ontario, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Assays are now pending from the first diamond drill holes completed as part of Viridian Metals Inc.'s (CSE: VRDN) (OTCQB: VIRMF) 2026 drill program at the Kraken project…

Read source
gurufocus.com

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines

Read source
businesswire.com

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare…

Read source
defenseworld.net

Viridian Therapeutics (NASDAQ:VRDN) and Zai Lab (NASDAQ:ZLAB) Financial Review

Zai Lab (NASDAQ: ZLAB - Get Free Report) and Viridian Therapeutics (NASDAQ: VRDN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the…

Read source
zacks.com

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.

Read source

Corporate actions

Corporate action history

Stock split

Effective Nov 13, 2020

1:15

Stock split

Effective Nov 7, 2016

1:15

VRDN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding VRDN

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
100.61M
Weight
0.88%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
63.5M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
56.66M
Weight
0.07%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
21.42M
Weight
0.02%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
18.38M
Weight
0.13%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
11.4M
Weight
0.05%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
9.59M
Weight
0.05%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
8.05M
Weight
0.05%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%

Continue in GoAI

Research VRDN

research.disclaimer